Literature DB >> 3258878

Quantitative immunological differences between newly diagnosed Graves' disease patients and relapsed patients.

U Di Mario1, F P Cavatorta, R Perfetti, G Pugliese, P Pozzilli, J Sutherland, M Vitillo, D Andreani.   

Abstract

Class 2-positive T cells, T-cell and mononuclear cell subsets, thyrotropin receptor antibodies (TRAb) and immune complexes were evaluated in 34 newly diagnosed Graves' patients and in 13 relapsed patients before a cycle of specific medical treatment. Class II-positive T lymphocytes were detected by monoclonal antibodies against different epitopes of class II antigens, whereas 4F2-positive cells were detected by 4F2 monoclonal antibody. 4F2-positive cells were statistically increased in newly diagnosed Graves' patients compared to relapsed patients (p less than 0.05). An increased percentage of class II activated T cells, detected by monoclonal antibodies L243, was found in newly diagnosed patients in comparison with relapsed subjects (p less than 0.025). Newly diagnosed Graves' patients showed a significant decrease in the ratio suppressor/cytotoxic T cells in comparison with normal control subjects but not with relapsed patients. Ninety-one % of newly diagnosed Graves' patients showed a high TRAb value, whereas only 69% of relapsed patients showed increased values (p less than 0.025). No difference was observed in the immune complex positivity between newly diagnosed Graves' patients and relapsed subjects. In conclusion, both humoral and cellular immune differences were found in relapsed patients vs newly diagnosed Graves' patients. The immunological abnormalities are quantitatively more pronounced in the latter group.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258878     DOI: 10.1007/BF03350108

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q.

Authors:  F C Hay; L J Nineham; I M Roitt
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

2.  Production of monoclonal antibodies reacting with peripheral blood mononuclear cell surface differentiation antigens.

Authors:  G S Eisenbarth; B F Haynes; J A Schroer; A S Fauci
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

3.  Immunological studies of autoimmune thyroid disorders: abnormalities in the inducer T cell subset and proliferative responses to autologous and allogeneic stimulation.

Authors:  C Fournier; H Chen; A Leger; J Charreire
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

4.  A method to facilitate the reading of up to 60 samples of monoclonal antibody-fluorescence stained cells using Medicell HLA-DR plates.

Authors:  M Sensi; P Pozzilli; U Di Mario
Journal:  J Clin Lab Immunol       Date:  1984-02

5.  Two populations of Ia-like molecules on a human B cell line.

Authors:  L A Lampson; R Levy
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

6.  Decreased suppressor T-lymphocytes in autoimmune thyroid diseases detected by monoclonal antibodies.

Authors:  V Sridama; F Pacini; L J DeGroot
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

7.  Analysis of T cell subsets in Graves' disease: alterations associated with carbimazole.

Authors:  M E Ludgate; A M McGregor; A P Weetman; S Ratanachaiyavong; J H Lazarus; R Hall; G W Middleton
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

8.  Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.

Authors:  J Charreire; G Karsenty; P Bouchard; G Schaison
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

9.  Human MHC class II molecules as differentiation markers.

Authors:  V van Heyningen; K Guy; R Newman; C M Steel
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

10.  Activated (Ia+) T-lymphocytes and their subsets in autoimmune thyroid diseases: analysis by dual laser flow microfluorocytometry.

Authors:  J Y Chan; P G Walfish
Journal:  J Clin Endocrinol Metab       Date:  1986-02       Impact factor: 5.958

View more
  1 in total

1.  Immunological aspects of Graves' disease patients in different clinical stages.

Authors:  A Gauna; G Segura; G Sartorio; R Soto; A Segal-Eiras
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.